Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(14):960; doi:10.1093/jnci/djj318
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

In Brief

The first 10% of the full text of this article appears below.

FDA Approves Chemotherapy for Cervical Cancer

The FDA has approved a two-drug combination for women with advanced cervical cancer who can't be treated with surgery or radiation.

The combination includes topotecan hydrochloride (Hycamtin) and cisplatin. Clinical trials suggested that it improves survival . . . [Full Text of this Article]

Pharmaceutical Sponsors Can Influence Physician Choices; Doctors Choose Their Drugs

Genetic Mutation Linked to Rare Adrenal Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?